Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Revenue per Share is $0.00 as of Mar. 2026. GuruFocus rates MLLCF with a GF Score™ of 34/100 and a GF Value™ of $0.51 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 769 Biotechnology companies, Molecular Partners AG ranks worse than 130038.88% on this metric.
Molecular Partners AG's revenue per share for the
three
months ended in Mar. 2026 was $0.00.
Molecular Partners AG's revenue per share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.
During the past 12 months, the average Revenue Per Share Growth Rate of Molecular Partners AG was -100.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Molecular Partners AG's Revenue per Share or its related term are showing as below:
During the past 13 years, Molecular Partners AG's highest 3-Year average Revenue Per Share Growth Rate was 81.60% per year. The lowest was -31.00% per year. And the median was -16.90% per year.
MLLCF's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Molecular Partners AG Revenue per Share Related Terms
Molecular Partners AG Revenue per Share Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MLLCF vs VRTX, REGN, RVMD: Revenue per Share Comparison
For the Biotechnology subindustry, Molecular Partners AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's PS Ratio falls into.
Molecular Partners AG Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Molecular Partners AG's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Revenue per Share of $0.00 as of Mar. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #999999 out of 769 companies in the Biotechnology industry.
Is Molecular Partners AG's Revenue per Share too high?
Molecular Partners AG's current Revenue per Share is $0.00. Based on the distribution chart, Molecular Partners AG ranks #999999 out of 769 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Molecular Partners AG has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Revenue per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #999999 out of 769 companies for Revenue per Share. This places Molecular Partners AG in the lower half of its industry. The industry median Revenue per Share is 3.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Biotechnology company?
The median Revenue per Share among Biotechnology companies is 3.00, based on 769 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Revenue per Share is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.51, compared to a current price of $3.80 — trading 645.1% above its estimated fair value. The current Revenue per Share is $0.00. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Revenue per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.80 is trading 645.1% above its estimated GF Value™ of $0.51.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Revenue per Share: $0.00
GF Value™: $0.51 vs. price of $3.80 (645.1% above fair value)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
